News

Tissue Testing Project

The Life Raft Group (LRG) is providing you with this information to let you know that comprehensive genomic profiling, also known as biomarker testing or molecular testing, is a crucial step in understanding the genomic factors that play a role in a GIST diagnosis. Bayer Pharmaceuticals, in partnership with The Life Raft Group (LRG), has extended a research collaboration to broaden access to comprehensive genomic testing (CGT) for Gastrointestinal Stromal Tumor (GIST) patients.

By |2021-11-04T10:18:38-04:00October 27th, 2021|Mutational Testing, News|

New Study Aids in the Diagnosis of Hereditary Paraganglioma and Pheochromocytoma

A recent study in Cancer Genetics, International initiative for a curated SDHB variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma, is important for GIST patients who carry a germline SDHB mutation

By |2021-09-09T11:41:15-04:00September 9th, 2021|News, Pediatric GIST, Research, SDH-Deficient GIST|

The Importance of Biomarker Testing for the Effective Treatment of GIST Patients – LRG Science

This issue of LRG Science presents six case studies as evidence that the practice of biomarker/mutational testing early in a GIST patient's journey is a critical path to the most effective treatment. Each patient was diagnosed with GIST, but did not receive mutational testing early enough to avoid suffering adverse side effects and wasting money on unnecessary, costly drugs.

By |2021-09-27T07:30:29-04:00August 30th, 2021|LRG Science, Mutational Testing, News|
Go to Top